u/griccioppo

Donanemab consistently slows disease progression across multiple complementary outcome measures. The benefits are clinically resonant, this is the kind of data that helps families understand what "slowing AD" actually looks like:

MCI → mild AD: 33% lower risk with donanemab (HR 0.67; NNT 8.5 over 76 weeks)
Mild → moderate AD: 50% lower risk (HR 0.50; NNT 21.4)

Overall NNT to prevent progression to next clinical stage: 9.1

Meaningful within-patient change (MWPC):
CDR-SB: 38% lower risk
iADRS: 30% lower risk

Link: https://www.neurology.org/doi/10.1212/CPJ.0000000000200621

Donanemab consistently slows disease progression across multiple complementary outcome measures. The benefits are clinically resonant, this is the kind of data that helps families understand what "slowing AD" actually looks like:

* MCI → mild AD: 33% lower risk with donanemab (HR 0.67; NNT 8.5 over 76 weeks)
* Mild → moderate AD: 50% lower risk (HR 0.50; NNT 21.4)

* ***Overall NNT to prevent progression to next clinical stage: 9.1***

* **Meaningful within-patient change (MWPC):**
* CDR-SB: 38% lower risk
* iADRS: 30% lower risk

Link: [https://www.neurology.org/doi/10.1212/CPJ.0000000000200621\](https://www.neurology.org/doi/10.1212/CPJ.0000000000200621)